Merck and Intercell said that the independent Data Monitoring Committee (DMC) has recommended to suspend the Phase II/III clinical trial evaluating V710, an investigational vaccine for the prevention of Staphylococcus aureus (S aureus) infection.
Subscribe to our email newsletter
The decision has been taken by DMC following a pre-specified interim analysis from the Phase II and III clinical trial.
The partners said the trial did not meet the pre-specified futility criteria and further analysis of the benefit-risk of the vaccine candidate will be initiated.
S. aureus causes hospital-acquired infections and 50% of strains isolated in hospitals globally are resistant to antibiotics.